NanoVibronix Expands Offerings with Introduction of PainShield Plus®
October 16 2020 - 8:30AM
Business Wire
One-of-a-Kind Therapeutic Device Enables
Tandem Treatment of Multiple Areas of Pain; U.S. Patent
Pending
NanoVibronix, Inc., (NASDAQ: NAOV), a medical device
company that produces the UroShield®, PainShield® and WoundShield®
Surface Acoustic Wave (SAW) Portable Ultrasonic Therapeutic
Devices, today announced the launch of the next generation of its
ultrasound pain management device, PainShield Plus® for the
treatment of multiple areas of pain in tandem.
This press release features multimedia. View
the full release here:
https://www.businesswire.com/news/home/20201016005064/en/
The New, Patent Pending PainShield
Plus
Brian Murphy, CEO of NanoVibronix, stated, “The introduction of
PainShield Plus is a natural extension of our highly effective
PainShield device. Increasingly, patients are seeking therapies
that work synergistically with more conventional treatment plans
and reduce the need for pharmaceuticals and surgical interventions.
We have extended the functionality of our core PainShield device to
include an additional transducer that enables patients to cover
twice the surface area for pain treatment and thereby broadens the
opportunities for application of this proven technology. Initial
responses from orthopedic and neurological patients and healthcare
providers have been overwhelmingly positive, and we are encouraged
by the prospects for wider distribution and use.”
The new, patent pending PainShield Plus includes a second
adhesive patch and transducer, which effectively doubles the
surface area that can be treated for pain in the same amount of
time. Each transducer covers approximately 20 cm2 of surface area
and with two points of access, bilateral treatment of orthopedic
pain is now possible with just one device.
Like the original, PainShield Plus utilizes ultrasound therapy
for the treatment of pain and various soft tissue injuries either
directly over joints or orthopedic hardware and without the need
for messy ultrasound gels. Importantly, the device is an effective
solution for avoiding opioid treatments and supports social
distancing by equipping patients to receive therapy independently
in the comfort and safety of their own homes.
PainShield is an ultrasound device, consisting of a reusable
driver unit and disposables, which includes a proprietary
therapeutic transducer and cover adhesive. PainShield delivers a
localized ultrasound effect to treat pain and induce soft tissue
healing in a targeted area, while keeping the level of ultrasound
energy at a safe and consistent level. Its range of applications
includes acute and chronic pain resolution through its many
mechanisms of action. PainShield can be used by patients at home or
work or in a clinical setting and can be used even while the
patient is sleeping. Patient benefits include ease of application
and use, faster recovery time, high compliance, and increased
safety and efficacy over existing devices that rely on
higher-frequency ultrasound.
About NanoVibronix, Inc.
NanoVibronix, Inc. (NASDAQ: NAOV) is a medical device company
headquartered in Elmsford, New York, with research and development
in Nesher, Israel, focused on developing medical devices utilizing
its patented low intensity surface acoustic wave (SAW) technology.
The proprietary technology allows for the creation of low-frequency
ultrasound waves that can be utilized for a variety of medical
applications, including for disruption of biofilms and bacterial
colonization, as well as for pain relief. The devices can be
administered at home without the assistance of medical
professionals. The Company’s primary products include PainShield®,
UroShield® and WoundShield®, all of which are portable devices
suitable for administration at home without assistance of medical
professionals. Additional information about NanoVibronix is
available at: www.nanovibronix.com.
Forward-looking Statements
This press release contains “forward-looking statements.” Such
statements may be preceded by the words “intends,” “may,” “will,”
“plans,” “expects,” “anticipates,” “projects,” “predicts,”
“estimates,” “aims,” “believes,” “hopes,” “potential” or similar
words. Forward-looking statements are not guarantees of future
performance, are based on certain assumptions and are subject to
various known and unknown risks and uncertainties, many of which
are beyond the Company’s control, and cannot be predicted or
quantified, and include, among others, statements regarding the
completion of the public offering, the satisfaction of customary
closing conditions related to the public offering and the intended
use of net proceeds from the public offering; consequently, actual
results may differ materially from those expressed or implied by
such forward-looking statements. Such risks and uncertainties
include, without limitation, risks and uncertainties associated
with: (i) the geographic, social and economic impact of COVID-19 on
the Company’s ability to conduct its business and raise capital in
the future when needed, (ii) market acceptance of our existing and
new products or lengthy product delays in key markets; (iii)
negative or unreliable clinical trial results; (iv) inability to
secure regulatory approvals for the sale of our products; (v)
intense competition in the medical device industry from much
larger, multinational companies,; (vi) product liability claims;
(vii) product malfunctions; (viii) our limited manufacturing
capabilities and reliance on subcontractor assistance; (ix)
insufficient or inadequate reimbursements by governmental and/or
other third party payers for our products; (x) our ability to
successfully obtain and maintain intellectual property protection
covering our products; (xi) legislative or regulatory reform
impacting the healthcare system in the U.S. or in foreign
jurisdictions; (xii) our reliance on single suppliers for certain
product components, (xiii) the need to raise additional capital to
meet our future business requirements and obligations, given the
fact that such capital may not be available, or may be costly,
dilutive or difficult to obtain; (xiv) our conducting business in
foreign jurisdictions exposing us to additional challenges, such
as, e.g., foreign currency exchange rate fluctuations, logistical
and communications challenges, the burden and cost of compliance
with foreign laws, and political and/or economic instabilities in
specific jurisdictions; and (xv) market and other conditions. More
detailed information about the Company and the risk factors that
may affect the realization of forward looking statements is set
forth in the Company’s filings with the Securities and Exchange
Commission (SEC), including the Company’s Annual Report on Form
10-K and its Quarterly Reports on Form 10-Q. Investors and security
holders are urged to read these documents free of charge on the
SEC’s web site at: http://www.sec.gov. The Company assumes no
obligation to publicly update or revise its forward-looking
statements as a result of new information, future events, or
otherwise, except as required by law.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20201016005064/en/
Investor Contacts: NanoVibronix, Inc.
bmurphy@nanovibronix.com (630) 338-5022 Or: Brett Maas, Managing
Principal, Hayden IR, LLC brett@haydenir.com (646) 536-7331
NanoVibronix (NASDAQ:NAOV)
Historical Stock Chart
From Mar 2024 to Apr 2024
NanoVibronix (NASDAQ:NAOV)
Historical Stock Chart
From Apr 2023 to Apr 2024